logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

The Gilead and Galapagos Agreement Is a Big Win for Both Firms and Their Shareholders

Gilead and Galapagos Global Research Collaboration Gilead Sciences ( GILD )   and Galapagos NV ( GLPG )   entered into a 10-year global research and development collaboration. Gilead will gain access to innovative compounds, including six molecules currently in...

Read More

July 15, 2019

0

Exelixis and Genentech (Roche) Combination Beats Untreated BRAF V600-Mutation Positive Advanced Melanoma

Exelixis Positive Results from IMspire 150 Exelixis ( EXEL ) announced positive results from IMspire 150;  the phase 3 trial of atezolizumab (TECENTRIQ®), cobimetinib (COTELLIC®) and vemurafenib (ZELBORAF®) in people with previously untreated BRAF V600 mutation-positive advanced melanoma.  The IMspire150...

Read More

December 13, 2019

0

Halozyme and argenx Most Recent News

Halozyme and argenx Collaboration argenx ( ARGX )   dosed the first subject in phase 1 clinical trial for the safety, pharmacokinetics, and pharmacodynamics of its product efgartigimod plus Halozyme's ( HALO ) drug delivery technology ENHANZE ® . The...

Read More

July 19, 2019

0

Amylyx Pharmaceuticals: Clinical Trial Results Demonstrate Statistically Significant Treatment Benefit in Lou Gehrig's Disease Patients

Amylyx Pharmaceuticals With the advancement of biological sciences, and increased information about the pathways of diseases, we are getting more interested in biotech firms that are focused on treating life-threatening diseases as the risk of failure is decreasing.  The successful...

Read More

December 17, 2019

0

RegenxBio Has Good News

RegenxBio License Agreement with Pfizer RegenxBio ( RGNX )   announced a license agreement with  Pfizer ( PFE ). Under the terms of the agreement RegenxBio has granted Pfizer a non-exclusive worldwide license, with rights to sublicense, to RegenxBio's NAV...

Read More

August 1, 2019

0

Rhythm Pharmaceuticals Has Good News. See Also: The Novartis News Story

Rhythm Pharmaceuticals From Rhythm Pharmaceuticals ( RYTM )   we learned that positive, top-line results from two pivotal Phase 3 clinical trials evaluating setmelanotide,   for pro-opiomelanocortin ( POMC ) and leptin receptor ( LEPR ) deficiency obesities, have met...

Read More

August 7, 2019

0

The FDA approved a combination of two products. Both belong to Array Biopharma

The FDA approved Array BioPharma’s (ARRY) products Braftovi™ capsules in combination with Mektovi ®  tablets for unresectable or metastatic skin cancer melanoma with a  BRAF  or  BRAF V mutation, as detected by an FDA-approved test. BRAFTOVI is not indicated for the...

Read More

June 28, 2018

0

Can Cassava Sciences Product PTI-125 Beat Alzheimer's Disease?

Cassava Sciences Stock is Rallying Cassava Sciences ( SAVA ) stock closed on Friday, December 27, 2019 at $5.21, reaching a 52-week high. Today, December 30, 2019 the stock is jumping higher, trading now at $6.40, UP $1.19 despite the...

Read More

December 30, 2019

0

The FDA Clears Compugen’s and Bayer’s IND Application for Their Checkpoint Inhibitor Immunotherapy Product

Finally, we are hearing what we were constantly expecting to hear coming out of Compugen’s (CGEN) technological capability. Yesterday, the U.S. Food and Drug Administration (FDA) has cleared Bayer AG’s investigational new drug (IND) application for BAY 1905254 , a...

Read More

July 3, 2018

0

Novartis Pleased the Market with Its Q2 Financial Results and Pleased Us with Its Great Scientific Achievements. See Also: The Role AveXis and RegenxBio are Playing Towards the Future Success of Novartis

Novartis’ (NVS) financials results exceeded analysts’ expectations . The firm’s research institutions’ strategy, well-designed structure, plans for innovation and accurate execution led to a wealthy and competitive pipeline with more than 200 projects in clinical development. Novartis is flying into...

Read More

July 19, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 70
  • 71
  • 72
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy